This topic contains a solution. Click here to go to the answer

Author Question: Determine the molarity of a solution formed by dissolving 97.7 g LiBr in enough water to yield 750.0 ... (Read 112 times)

jenna1

  • Hero Member
  • *****
  • Posts: 568
Determine the molarity of a solution formed by dissolving 97.7 g LiBr in enough water to yield 750.0 mL of solution.
 
  A) 1.50 M
  B) 1.18 M
  C) 0.130 M
  D) 0.768 M
  E) 2.30 M

Question 2

Determine the concentration of a solution prepared by diluting 25.0 mL of a stock 0.188 M Ca(NO3)2 solution to 150.0 mL.
 
  A) 1.13 M
  B) 0.0887 M
  C) 0.0313 M
  D) 0.0199 M
  E) 0.0501 M



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

asdfghjkl;

  • Sr. Member
  • ****
  • Posts: 323
Answer to Question 1

A

Answer to Question 2

C




jenna1

  • Member
  • Posts: 568
Reply 2 on: Aug 27, 2018
:D TYSM


peter

  • Member
  • Posts: 330
Reply 3 on: Yesterday
Excellent

 

Did you know?

In the United States, congenital cytomegalovirus causes one child to become disabled almost every hour. CMV is the leading preventable viral cause of development disability in newborns. These disabilities include hearing or vision loss, and cerebral palsy.

Did you know?

Acetaminophen (Tylenol) in overdose can seriously damage the liver. It should never be taken by people who use alcohol heavily; it can result in severe liver damage and even a condition requiring a liver transplant.

Did you know?

Congestive heart failure is a serious disorder that carries a reduced life expectancy. Heart failure is usually a chronic illness, and it may worsen with infection or other physical stressors.

Did you know?

If you use artificial sweeteners, such as cyclamates, your eyes may be more sensitive to light. Other factors that will make your eyes more sensitive to light include use of antibiotics, oral contraceptives, hypertension medications, diuretics, and antidiabetic medications.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library